Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 7/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14033079 | 0.80 | ALDH1A1 (0.53) | KDM4EALDH1A1POLB | |
| SCHEMBL4564181 | 0.78 | PDE2A (0.42) | KDM4EALDH1A1PDE2AHSD11B1 | |
| SCHEMBL12505413 | 0.77 | IRAK4 (0.43) | KDM4EALDH1A1TDP1PDE2APOLB | |
| SCHEMBL15333599 | 0.77 | LPL (0.32) | PDE2A | |
| SCHEMBL310126 | 0.76 | PDE2A (0.59) | KDM4EALDH1A1TDP1PDE2AHSD11B1 | |
| SCHEMBL310362 | 0.76 | HSD11B1 (0.49) | KDM4EALDH1A1TDP1PDE2AHSD11B1 | |
| SCHEMBL28667748 | 0.76 | KDM4E (0.41) | KDM4EALDH1A1TDP1PDE2APOLB | |
| SCHEMBL309283 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1TDP1PDE2A | |
| SCHEMBL310187 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1TDP1PDE2APOLB | |
| SCHEMBL23728540 | 0.75 | PDE2A (0.43) | KDM4EALDH1A1TDP1PDE2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3642204-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2018234345-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008116898-A1 | PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE | BIOVITRUM AB (PUBL) (SE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | KDM4E 379/4885ALDH1A1 1232/4885TDP1 144/4885 |
| US-20080255153-A1 | New compounds | SCD, SCD5, FADS2 | KDM4E 1192/4885ALDH1A1 1498/4885TDP1 2450/4885 |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | KDM4E 379/4885ALDH1A1 1232/4885TDP1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.